Cancer-Killing virus trial launches for melanoma that spread to brain

NCT ID NCT07444606

Not yet recruiting Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a virus called DNX-2401, designed to infect and destroy melanoma cells in the brain and body. About 50 adults with stage IV melanoma will receive injections to find the safest dose and number of treatments. The main goal is to check for side effects, not yet to prove the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DNX-2401 (an oncolytic virus that infects and kills cancer cells)
What this could lead to: If it works, this could point toward a new treatment option for melanoma that has spread to the brain and other parts of the body.
What could go wrong: This is a very early phase 1 trial with only 50 participants, focused on safety and dosing. It is not yet known if DNX-2401 will shrink tumors or improve survival, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.